"Sex differences in the pathological progression of AD call for sex-specific timing considerations when administrating anti-Aβ and anti-tau treatments."
The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Researchers identified segment-specific effects of immune cells on intestinal contractions, providing new angles for managing inflammatory bowel disease.
Misdiagnosis can lead to inappropriate treatment, potentially subjecting patients to unnecessary toxicity or, conversely, inadequate treatment for a life-threatening cancer.
Investigators discovered that measuring the interaction between the RAS and RAF proteins could provide valuable insights into the effectiveness of treatments in patients with KRAS G12C–mutated NSCLC.